Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKTX NASDAQ:CGTX NASDAQ:TELO NASDAQ:TLPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$1.13$1.22$0.85▼$4.40$36.36M0.2131,209 shs47,264 shsCGTXCognition Therapeutics$0.65-3.8%$0.37$0.22▼$2.54$40.54M0.884.23 million shs3.13 million shsTELOTelomir Pharmaceuticals$2.28+88.4%$1.82$1.12▼$8.40$67.86M-0.9850,565 shs136.65 million shsTLPHTalphera$0.41-4.7%$0.48$0.38▼$1.19$8.40M-0.11138,486 shs205,967 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics0.00%-0.06%-1.74%-6.15%-70.50%CGTXCognition Therapeutics0.00%+15.26%+133.57%+75.62%-65.94%TELOTelomir Pharmaceuticals0.00%+96.55%+29.55%-8.06%-42.42%TLPHTalphera0.00%-21.17%-15.83%-14.78%-55.45%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKTXAkari Therapeutics2.9691 of 5 stars3.53.00.00.02.63.30.0CGTXCognition Therapeutics2.9974 of 5 stars3.53.00.00.03.11.70.6TELOTelomir Pharmaceuticals2.9365 of 5 stars3.83.00.00.01.90.00.6TLPHTalphera1.6361 of 5 stars3.82.00.00.00.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKTXAkari Therapeutics 3.00Buy$5.00342.48% UpsideCGTXCognition Therapeutics 3.00Buy$2.83333.23% UpsideTELOTelomir Pharmaceuticals 3.50Strong Buy$15.00557.89% UpsideTLPHTalphera 3.50Strong Buy$5.001,119.81% UpsideCurrent Analyst Ratings BreakdownLatest TLPH, AKTX, CGTX, and TELO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/18/2025AKTXAkari TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$5.006/26/2025CGTXCognition TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.005/27/2025CGTXCognition TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $3.005/8/2025CGTXCognition TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $4.00(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKTXAkari TherapeuticsN/AN/AN/AN/A$0.84 per shareN/ACGTXCognition TherapeuticsN/AN/AN/AN/A$0.31 per shareN/ATELOTelomir PharmaceuticalsN/AN/AN/AN/A$0.02 per shareN/ATLPHTalphera$650K12.93N/AN/A$0.47 per share0.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKTXAkari Therapeutics-$19.79MN/A0.00∞N/AN/A-213.59%-65.60%8/18/2025 (Estimated)CGTXCognition Therapeutics-$33.97M-$0.74N/AN/AN/AN/A-194.42%-115.14%8/6/2025 (Estimated)TELOTelomir Pharmaceuticals-$16.53M-$0.42N/AN/AN/AN/A-2,009.40%-1,009.72%8/12/2025 (Estimated)TLPHTalphera-$13M-$0.45N/AN/AN/AN/A-130.28%-59.25%8/13/2025 (Estimated)Latest TLPH, AKTX, CGTX, and TELO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CGTXCognition Therapeutics-$0.11N/AN/AN/AN/AN/A8/13/2025Q2 2025TLPHTalphera-$0.1150N/AN/AN/AN/AN/A8/12/2025N/ATELOTelomir Pharmaceuticals-$0.08N/AN/AN/AN/AN/A5/12/2025Q1 2025TELOTelomir Pharmaceuticals-$0.10-$0.07+$0.03-$0.07N/AN/A5/6/2025Q1 2025CGTXCognition Therapeutics-$0.12-$0.14-$0.02-$0.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKTXAkari TherapeuticsN/AN/AN/AN/AN/ACGTXCognition TherapeuticsN/AN/AN/AN/AN/ATELOTelomir PharmaceuticalsN/AN/AN/AN/AN/ATLPHTalpheraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKTXAkari TherapeuticsN/A0.160.16CGTXCognition TherapeuticsN/A2.092.09TELOTelomir PharmaceuticalsN/A0.750.75TLPHTalpheraN/A3.113.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKTXAkari Therapeutics5.06%CGTXCognition Therapeutics43.35%TELOTelomir PharmaceuticalsN/ATLPHTalphera37.67%Insider OwnershipCompanyInsider OwnershipAKTXAkari Therapeutics38.10%CGTXCognition Therapeutics14.40%TELOTelomir PharmaceuticalsN/ATLPHTalphera3.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKTXAkari Therapeutics932.18 million19.92 millionNot OptionableCGTXCognition Therapeutics2061.99 million53.07 millionNot OptionableTELOTelomir Pharmaceuticals129.76 millionN/AN/ATLPHTalphera1920.50 million19.85 millionOptionableTLPH, AKTX, CGTX, and TELO HeadlinesRecent News About These Companiestalphera receives extension to meet nasdaq listing requirementsJune 7, 2025 | investing.comTalphera Granted Extension for Nasdaq ComplianceJune 5, 2025 | tipranks.comTalphera, Inc.: Talphera Announces First Quarter 2025 Financial Results and Provides Corporate UpdateMay 17, 2025 | finanznachrichten.deEarnings call transcript: Talphera Inc. outlines strategic shifts in Q1 2025May 16, 2025 | uk.investing.comTalphera, Inc. (NASDAQ:TLPH) Q1 2025 Earnings Call TranscriptMay 16, 2025 | msn.comTalphera outlines accelerated NEPHRO CRRT study timeline with completion targeted by end of 2025, supported by new site activations and $14.8M financingMay 15, 2025 | msn.comTalphera, Inc. (TLPH) Q1 2025 Earnings Call TranscriptMay 14, 2025 | seekingalpha.comTalphera Announces First Quarter 2025 Financial Results and Provides Corporate UpdateMay 14, 2025 | prnewswire.comTalphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025May 7, 2025 | prnewswire.comAll You Need to Know About Talphera (TLPH) Rating Upgrade to Strong BuyMay 7, 2025 | msn.comTalphera (TLPH) Upgraded to Buy: What Does It Mean for the Stock?April 5, 2025 | msn.comTalphera reports Q4 EPS (7c) vs. (25c) last yearApril 1, 2025 | markets.businessinsider.comTalphera, Inc. (NASDAQ:TLPH) Q4 2024 Earnings Call TranscriptApril 1, 2025 | msn.comTalphera announces agreement with FDA to reduce NEPHRO CRRT study sizeApril 1, 2025 | markets.businessinsider.comTalphera Reports 2024 Financial Results and Study UpdateMarch 31, 2025 | tipranks.comTalphera outlines 2025 timeline for NEPHRO CRRT study completion and FDA approval of NiyadMarch 31, 2025 | msn.comTalphera, Inc. (TLPH) Q4 2024 Earnings Call TranscriptMarch 31, 2025 | seekingalpha.comTalphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 31, 2025 | prnewswire.comTalphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 MillionMarch 31, 2025 | prnewswire.com7TLPH : Earnings Outlook For TalpheraMarch 28, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTLPH, AKTX, CGTX, and TELO Company DescriptionsAkari Therapeutics NASDAQ:AKTX$1.13 0.00 (0.00%) Closing price 07/18/2025 03:59 PM EasternExtended Trading$1.14 +0.01 (+0.88%) As of 07/18/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.Cognition Therapeutics NASDAQ:CGTX$0.65 -0.03 (-3.82%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$0.66 +0.01 (+1.38%) As of 07/18/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.Telomir Pharmaceuticals NASDAQ:TELO$2.28 +1.07 (+88.43%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$2.15 -0.13 (-5.70%) As of 07/18/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.Talphera NASDAQ:TLPH$0.41 -0.02 (-4.67%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$0.42 +0.01 (+1.73%) As of 07/18/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
